PUBLISHER: The Business Research Company | PRODUCT CODE: 2104674
PUBLISHER: The Business Research Company | PRODUCT CODE: 2104674
Quinine is a natural compound extracted from the bark of the cinchona tree, traditionally used to treat malaria. It works by interfering with the growth and reproduction of the malaria parasite in red blood cells.
The quinine market consists of sales by entities (organizations, sole traders and partnerships) of quinine that is used by healthcare providers, hospitals, clinics, and patients, particularly in regions where malaria is prevalent or where quinine-based therapies are prescribed for muscle cramps. It is typically used when patients require treatment for malaria infections caused by Plasmodium parasites, especially in cases where resistance to other antimalarial drugs is observed, and also for managing nocturnal leg cramps under controlled medical supervision.
The global quinine market was valued at $1,754.0 million in 2020 which grew till 2025 at a compound annual growth rate (CAGR) of more than 7.00%.
Public-Private Partnerships In Malaria Eradication Programs
During historic period, public-private partnerships in malaria eradication programs supported the growth of the quinine market. Collaborations between governments, pharmaceutical companies, and global health organizations enabled efficient funding, production, and distribution of antimalarial treatments. These partnerships enhanced supply chain capabilities, improved access to medicines in remote and high burden regions and ensured consistent availability of quinine for severe malaria cases. Additionally, joint initiatives focused on awareness campaigns, early diagnosis, and treatment adherence, further driving demand. For instance, in April 2024, Benin, Liberia, and Sierra Leone have rollout large-scale malaria vaccine, marking a major step in child health protection across West Africa. Announced on World Malaria Day, the initiative targets millions of children and expands the number of African countries offering malaria vaccines to eight. Supported by Gavi, a Switzerland-based vaccine alliance, World Health Organization (WHO), a Switzerland-based intergovernmental organization, and United Nations Children's Fund (UNICEF), a US-based organization the rollout integrates vaccines such as RTS, S and R21 into national immunization programmes alongside existing measures like insecticide-treated nets. Early deployments include hundreds of thousands of doses, with nationwide expansion planned. The move follows successful pilot programmes that reduced child mortality and hospitalizations, aiming to curb the region's high malaria burden and strengthen prevention efforts. Therefore, public-private partnerships in malaria eradication programs drove the growth of the quinine market.
Biotechnology, Genomics And Precision Medicine
Major companies operating in the quinine market are focusing on biotechnological and enzyme-driven production methods to enable sustainable, scalable, and cost-efficient synthesis of quinine and its derivatives, reducing dependence on traditional plant extraction while accelerating pharmaceutical innovation. For instance, in March 2026, scientists have successfully decoded the biosynthesis of quinine in the Cinchona tree, marking a major breakthrough in malaria drug production. Researchers identified key enzymes, including transferases, a dioxygenase, and a cytochrome P450, that drive the formation of quinine and related alkaloids. By mapping previously unknown intermediates and enzymatic steps, the study resolves a century-old scientific challenge. This discovery enables sustainable, lab-based production of quinine, reducing reliance on bark extraction from plantations. It also opens pathways to develop new therapeutic derivatives, advancing both pharmaceutical innovation and cost-effective malaria treatment, particularly in high-burden regions where demand for quinine remains significant.
The global quinine market is highly fragmented, with large number of small players operating in the market. The top 10 competitors in the market made up 4.772% of the total market in 2024.
Quinine Global Market Opportunities And Strategies To 2035 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global quinine market as it emerges from the COVID-19 shut down.
Where is the largest and fastest-growing market for quinine? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The quinine market global report from The Business Research Company answers all these questions and many more.
The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider quinine market; and compares it with other markets.